頁籤選單縮合
題名 | Crizotinib與分子病理學的檢測=Crizotinib and Molecular Pathology for Lung Cancer Target Therapy |
---|---|
作者姓名(中文) | 宋慧蒂; 項怡平; 吳佳哲; | 書刊名 | 藥學雜誌 |
卷期 | 29:4=117 2013.12[民102.12] |
頁次 | 頁39-43 |
分類號 | 418.31 |
關鍵詞 | 標靶治療; 分子病理檢測; Crizotinib; EGFR; EML4-ALK; |
語文 | 中文(Chinese) |
中文摘要 | 近10年癌症的治療發展仍是以標靶治療為主流,由於生物技術和癌症生物學的進步而引入癌症個人化治療的概念。腫瘤的個人化用藥,包括使用生物標記檢測,可當做選擇最佳標靶藥物的治療目標。預測性的生物標記可識別最有可能從治療中獲益的患者族群。以肺癌的治療而言,病理分類必須在很小的標的上進行許多檢測,包括以免疫組織化學染色 (IHC)、直接定序或是 Scorpion ARMS等方式偵測上皮生長因子 (EGFR)突變;若 EGFR有突變可考慮使用 gefitnib等標靶治療藥品;若 EGFR沒有突變,接著以 IHC、RT-PCR或 FISH等方分子診斷式檢測變性淋巴瘤激酶 (EML4-ALK)變異;若 EML4-ALK有變異可考慮使用 crizotinib;若 EML4-ALK沒有變異則需檢測 KARS突變,再根據整體的檢測結果提供不同的個別治療建議。 |
英文摘要 | Targeted therapy has been the state-of-the-art treatment for lung cancer in the last decade. The progress in biotechnology and knowledge of cancer biology has led us to the concept of personalized medicine in oncology. The molecular testing for biomarkers is critical in selecting the optimal therapeutic targets for targeted cancer therapy; prediction biomarkers help screen out the patient populations that are most responding to the targeted therapy. Taking lung cancer treatment as an example, a series of molecular tests can be performed on a small piece of biopsy tissue, including immunohistochemistry, direct sequencing, or Scorpion-ARMS real-time PCR for EGFR mutations. When the testing for EGFR mutation is negative, the immunohistochemistry, reverse-transcription PCR or fluorescence in situ hybridization tests for EML4-ALK translocations will be applied. K-ras mutation analysis will follow if the testing for EGFR mutation and ALK translocation is negative. The management for lung cancer will be evaluated when comprehensive molecular information has been documented. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。